SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a novel T cell checkpoint
- Hadassah Hebrew University Hospital, Israel
- Broad Institute of MIT and Harvard, United States
- The Children's Hospital of Philadelphia, United States
- McGill University, Canada
Peer review process
This article was accepted for publication via eLife's original publishing model. eLife publishes the authors' accepted manuscript as a PDF only version before the full Version of Record is ready for publication. Peer reviews are published along with the Version of Record.
History
- Version of Record published
- Accepted Manuscript published
- Accepted
- Received
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a novel T cell checkpoint
eLife 9:e52539.
https://doi.org/10.7554/eLife.52539
